Outcomes of left ventricular assist device implantation for advanced heart failure in critically ill patients (INTERMACS 1 and 2): A retrospective study.
INTERMACS
adverse events
critically ill
heart failure
left ventricular assist device
Journal
Artificial organs
ISSN: 1525-1594
Titre abrégé: Artif Organs
Pays: United States
ID NLM: 7802778
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
revised:
27
11
2020
received:
24
08
2020
accepted:
17
12
2020
pubmed:
23
12
2020
medline:
15
12
2021
entrez:
22
12
2020
Statut:
ppublish
Résumé
The use of left ventricular assist devices (LVADs) for advanced heart failure is becoming increasingly common. However, optimal timing and patient selection remain controversial. The aim of this study was to investigate outcomes of LVAD implantation for advanced heart failure in critically ill patients (INTERMACS 1 and 2). Between August 2010 and January 2020, 207 consecutive patients underwent LVAD implantation. Overall survival, major adverse events, and laboratory parameters were compared between patients in INTERMACS 1-2 (n = 107) and INTERMACS 3-5 (n = 100). Preoperative white blood cells, C-reactive protein, procalcitonin, bilirubin, alanine transaminase, and lactate dehydrogenase were all significantly higher in INTERMACS 1-2 when compared to INTERMACS 3-5 (P < .05). During hospitalization following LVAD implantation, patients in INTERMACS 1-2 were more likely to develop major infections (41.1% vs. 23.0%, P = .005), respiratory failure (57.9% vs. 25.0%, P < .001), mild (20.6% vs. 8.0%, P = .010), and moderate (31.8% vs. 7.0%, P < .001) right heart failure, and acute renal dysfunction (56.1% vs. 6.0%, P < .001). During a median follow-up of 2.00 years (interquartile range (IQR) 0.24-3.39 years), they had a higher incidence of thoracic (15.9% vs. 4.0%, P = .005) and gastrointestinal bleeding (21.5% vs. 11.0%, P = .042), as well as right heart failure (18.7% vs. 1%, P < .001). Risk of death was significantly higher in the INTERMACS 1-2 group (hazards ratio (HR) 1.64, 95% CI 1.12-2.40, P = .011). LVAD implantation in critically ill patients is associated with increased morbidity and mortality. Our results suggest that decision for LVAD should be not be delayed until INTERMACS 1 and 2 levels whenever possible.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
706-716Informations de copyright
© 2020 International Center for Artificial Organs and Transplantation and Wiley Periodicals LLC.
Références
Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail. 2001;3(3):283-91. https://doi.org/10.1016/s1388-9842(01)00123-4
Bleumink GS, Knetsch AM, Sturkenboom MCJM, Straus SMJM, Hofman A, Deckers JW, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J. 2004;25(18):1614-9. https://doi.org/10.1016/j.ehj.2004.06.038
Zhigalov K, Michel Pompeu Barros Oliveira S, Safonov D, et al. Clinical outcomes of venoarterial extracorporeal life support in 462 patients: Single-center experience. Artif Organs. 2020;44(6):620-7. https://doi.org/10.1111/aor.13625
Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435-43. https://doi.org/10.1056/NEJMoa012175
Mehra MR, Uriel N, Naka Y, Cleveland JC, Yuzefpolskaya M, Salerno CT, et al. A fully magnetically levitated left ventricular assist device - final report. N Engl J Med. 2019;380(17):1618-27. https://doi.org/10.1056/NEJMoa1900486
Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, et al. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med. 2017;376(5):451-60. https://doi.org/10.1056/NEJMoa1602954
Zhigalov K, Mashhour A, Szczechowicz M, Mkalaluh S, Karagezian S, Gogia I, et al. Clinical outcome and comparison of three different left ventricular assist devices in a high-risk cohort. Artif Organs. 2018;42(11):1035-42. https://doi.org/10.1111/aor.13140
Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(11):1505-35. https://doi.org/10.1002/ejhf.1236
Gustafsson F, Rogers JG. Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes. Eur J Heart Fail. 2017;19(5):595-602. https://doi.org/10.1002/ejhf.779
Holman WL. Advances in mechanical circulatory support Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) what have we learned and what will we learn? Circulation. 2012;126(11):1401-6. https://doi.org/10.1161/CIRCULATIONAHA.112.097816
Stewart GC, Kittleson MM, Patel PC, Cowger JA, Patel CB, Mountis MM, et al. INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) profiling identifies ambulatory patients at high risk on medical therapy after hospitalizations for heart failure. Circ Hear Fail. 2016;9(11): https://doi.org/10.1161/CIRCHEARTFAILURE.116.003032
Teuteberg JJ, Cleveland JC, Cowger J, Higgins RS, Goldstein DJ, Keebler M, et al. THE SOCIETY OF THORACIC SURGEONS INTERMACS ANNUAL REPORT The Society of Thoracic Surgeons Intermacs 2019 Annual Report: the changing landscape of devices and indications. Ann Thorac Surg. 2020;109(3):649-60. https://doi.org/10.1016/j.athoracsur.2019.12.005
Kirklin JK, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers SL, et al. Eighth annual INTERMACS report: special focus on framing the impact of adverse events. J Hear Lung Transplant. 2017;36:1080-6. https://doi.org/10.1016/j.healun.2017.07.005
INTERMACS Executive Committee. INTERMACS Adverse Event Definitions: Adult and Pediatric Patients. 2013 [cited 2020 Oct 18]. Available from: https://www.uab.edu/medicine/intermacs/images/protocol_4.0/protocol_4.0_MoP/Appendix_A_INTERMACS_AE_Definitions__05152013.docx
Pilarczyk K, Carstens H, Papathanasiou M, Luedike P, Koch A, Jakob H, et al. Prediction of acute kidney injury after left ventricular assist device implantation: evaluation of clinical risk scores. Artif Organs. 2020;44(2):162-73. https://doi.org/10.1111/aor.13548
Hanke JS, Dogan G, Zoch A, Ricklefs M, Wert L, Feldmann C, et al. One-year outcomes with the HeartMate 3 left ventricular assist device. J Thorac Cardiovasc Surg. 2018;156(2):662-9. https://doi.org/10.1016/j.jtcvs.2018.01.083
Kanwar MK, McIlvennan CK, Lohmueller LC, Bailey SH, Rogers JG, Teuteberg J, et al. Defining optimal outcomes in patients with left ventricular assist devices. ASAIO J. 2020. https://doi.org/10.1097/mat.0000000000001228
Kormos RL, Cowger J, Pagani FD, Teuteberg JJ, Goldstein DJ, Jacobs JP, et al. The Society of Thoracic Surgeons Intermacs Database Annual Report: evolving indications, outcomes, and scientific partnerships. Ann Thorac Surg. 2019;107(2):341-53. https://doi.org/10.1016/j.athoracsur.2018.11.011
Michelis KC, Zhong L, Peltz M, Pandey A, Tang WHW, Rohatgi A, et al. Dynamic forecasts of survival for patients living with destination left ventricular assist devices: insights from INTERMACS. J Am Heart Assoc. 2020;9(14):e016203. https://doi.org/10.1161/JAHA.119.016203
Kanwar MK, Lohmueller LC, Kormos RL, Teuteberg JJ, Rogers JG, Lindenfeld JA, et al. A Bayesian model to predict survival after left ventricular assist device implantation. JACC Hear Fail. 2018;6(9):771-9. https://doi.org/10.1016/j.jchf.2018.03.016
Seese L, Movahedi F, Antaki J, Kilic A, Padman R, Zhang Y, et al. Delineating pathways to death by multisystem organ failure in patients with a left ventricular assist device. Ann Thorac Surg. 2020. https://doi.org/10.1016/j.athoracsur.2020.05.164
Carmona A, Minh TH, Perrier S, Schneider C, Marguerite S, Ajob G, et al. Minimally invasive surgery for left ventricular assist device implantation is safe and associated with a decreased risk of right ventricular failure. J Thorac Dis. 2020;12(4):1496-1506. https://doi.org/10.21037/jtd.2020.02.32
Mori M, McCloskey G, Geirsson A, Mangi AA, Yun JJ, Jacoby D, et al. Improving outcomes in INTERMACS category 1 patients with pre-LVAD, awake venous-arterial extracorporeal membrane oxygenation support. ASAIO J. 2019;65(8):819-26. https://doi.org/10.1097/MAT.0000000000000908
Bertoldi LF, Pappalardo F, Lubos E, Grahn H, Rybczinski M, Barten MJ, et al. Bridging INTERMACS 1 patients from VA-ECMO to LVAD via Impella 5.0: de-escalate and ambulate. J Crit Care. 2020;57:259-63. https://doi.org/10.1016/j.jcrc.2019.12.028